Pfizer fails phase 3 C. diff vaccine test but still spies possible path forwardnews2022-03-01T13:05:27+00:00March 1st, 2022|FierceBiotech|
UPDATE: Editas shares boosted as patent office rules in favor of Broad’s CRISPR patents, but the fight will continuenews2022-03-01T00:49:51+00:00March 1st, 2022|FierceBiotech|
Intellia now has the data for No. 1 unanswered gene editing question: Does it last?news2022-02-28T19:56:55+00:00February 28th, 2022|FierceBiotech|
Gemini CEO out the door as 80% of staff laid off, strategic review gets underwaynews2022-02-28T16:28:16+00:00February 28th, 2022|FierceBiotech|
FDA sticks a fork in Reata’s treatment for chronic kidney diseasenews2022-02-28T16:00:09+00:00February 28th, 2022|FierceBiotech|
Amryt’s shares tumble as FDA stiff-arms skin treatment, a month after EU delay revealednews2022-02-28T15:56:08+00:00February 28th, 2022|FierceBiotech|
Huadong buys into Heidelberg, signs nearly $1B deal to gain access to four cancer assetsnews2022-02-28T15:35:29+00:00February 28th, 2022|FierceBiotech|
Blueprint marks protein degrader path in $632M biobucks pact with a Vantnews2022-02-28T13:50:55+00:00February 28th, 2022|FierceBiotech|
Deaths in Keytruda combo study spur Celyad to pause trial of off-the-shelf CAR-T cell therapynews2022-02-28T11:37:07+00:00February 28th, 2022|FierceBiotech|
Advantage Pfizer: GSK stops phase 3 trials of maternal RSV vaccine after seeing safety signalnews2022-02-28T10:41:33+00:00February 28th, 2022|FierceBiotech|
